BridgeBio Pharma
BBIO
BBIO
164 hedge funds and large institutions have $1.28B invested in BridgeBio Pharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 59 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
164
Holders Change
-14
Holders Change %
-7.87%
% of All Funds
2.77%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
59
Reduced
59
Closed
26
Calls
$9.02M
Puts
$3.53M
Net Calls
+$5.49M
Net Calls Change
-$501K
Top Buyers
| 1 |
1
State Street
Boston,
Massachusetts
|
$99.5M |
| 2 |
LCM
2
Laurion Capital Management
New York
|
$13.4M |
| 3 |
AC
3
Aristeia Capital
Greenwich,
Connecticut
|
$4.99M |
| 4 |
4
Vanguard Group
Malvern,
Pennsylvania
|
$89.9M |
| 5 |
5
Citadel Advisors
Miami,
Florida
|
$7.64M |
